Novel, Orally Bioavailable γ-Aminoamide CC Chemokine Receptor 2
Por um escritor misterioso
Descrição
Full article: Future therapeutic treatment of COPD: Struggle between oxidants and cytokines
Novel peptide nanoparticle–biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness - ScienceDirect
CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV. - Abstract - Europe PMC
A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6+ T Cells, and Ameliorates Interleukin-23-Induced Skin Inflammation
Targeting lung inflammation: novel therapies for the treatment of COPD. - Abstract - Europe PMC
Full article: Chemokine receptor antagonists: Part 1
Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2
CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV. - Abstract - Europe PMC
The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities
Pharmaceuticals, Free Full-Text
Selective and Dual Targeting of CCR2 and CCR5 Receptors: A Current Overview
Recent updates for designing CCR5 antagonists as anti-retroviral agents - ScienceDirect
Targeting lung inflammation: novel therapies for the treatment of COPD. - Abstract - Europe PMC
Full article: Chemokine receptor antagonists: Part 1
de
por adulto (o preço varia de acordo com o tamanho do grupo)
